Novartis receives FDA approval for Rhapsido in symptomatic dermographism
FROM THE WIRE · FINANCE.YAHOO.COM
Novartis Pharma AG In Phase III RemIND trial, twice as many adults taking Rhapsido achieved complete hive resolution by Week 12 vs placebo, with responses seen by Week 21 SD is most prevalent type of chronic inducible urticaria (CIndU)2; more than 50% of patients remain…
Read at the source ↗MARKET IMPACTHIGH✦ News Impact agent estimateTone: expected bullishFDA approval for new Rhapsido indication expands potential market and drug value.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Rhapsido is the first approved treatment for symptomatic dermographism in adults inadequately controlled by antihistamines.
- 02In the RemIND trial, twice as many patients achieved complete hive resolution by week 12 versus placebo.
- 03Approval builds on Rhapsido's established safety profile and expands BTK inhibitor use in immune-mediated diseases.
NEWS IMPACT AND MARKET REACTIONChange from the reference price
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets